Beximco Pharma beats major peers in nine-month revenue growth

Beximco Pharmaceuticals PLC reported a 13.1 percent year-on-year growth in its revenue in the first nine months of the 2025-26 financial year, outpacing its peers, according to an earnings update released by BRAC EPL Stock Brokerage yesterday.

The company recorded Tk 4,142 crore in net revenue during the July-March period of the 2025-26 financial year, up from Tk 3,662 crore a year earlier.

Tap Here to Add The Daily Star As A Trusted Source

BRAC EPL Stock Brokerage Ltd said Square Pharma recorded a 12.5 percent year-on-year growth in revenue, while Renata posted more than 6.5 percent year-on-year growth in sales during the period.

"Domestic sales remained the primary growth driver, expanding 14.4 percent year-on-year. Export revenue grew a modest 1.2 percent in this financial year from a year ago," said the firm in the update.

Beximco Pharma was able to contain its cost of goods sold, which increased by 6.5 percent year-on-year.

BRAC EPL Stock Brokerage said this provided significant operating leverage to the company.

Beximco Pharma published its financials after the Bangladesh Securities and Exchange Commission (BSEC) allowed the company to hold a special board meeting to approve and publish its outstanding financial reports.

These included the third-quarter financial statements for the 2024-25 financial year, the audited annual report, and the first-, second- and third-quarter reports for the 2025-26 financial year.

The move cleared the company's reporting backlog of 15 months, allowing the London Stock Exchange to lift the suspension and resume trading of the global depositary receipts from June 26.

The pharmaceuticals maker had been unable to convene board meetings to approve and publish its financial statements due to ongoing legal proceedings before the High Court.

Beximco Pharma recorded a 32.7 percent year-on-year growth in profit after tax to Tk 694 crore in the first nine months of the 2025-26 financial year.

BRAC EPL said the earnings were driven by strong revenue momentum, disciplined direct cost management, and continued deleveraging.

BRAC EPL said Beximco Pharma delivered a solid 10.7 percent year-on-year revenue growth in FY25 despite operating under prolonged legal uncertainties throughout the year.